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Objective. Single-session radiosurgery with Gamma Knife (GK) may be a potential adjuvant treatment in acromegaly. We analyzed
the safety and eﬃcacy of GK in patients who had previously received maximal surgical debulking at our hospital. Methods.T h e
studywasaretrospectiveanalysisofhormonal,radiological,andophthalmologicdatacollectedinapredeﬁnedprotocolfrom1994
to2009.Themeanageattreatmentwas42.3years(range22–67yy).103acromegalicpatientsparticipatedinthestudy.Themedian
follow-up was 71 months (IQ range 43–107). All patients were treated with GK for residual or recurrent GH-secreting adenoma.
Results. Sixty-three patients (61.2%) reached the main outcome of the study. The rate of remission was 58.3% at 5 years (95% CI
47.6–69.0%). Other 15 patients (14.6%) were in remission after GK while on treatment with somatostatin analogues. No serious
side eﬀects occurred after GK. Eight patients (7.8%) experienced a new deﬁcit of pituitary function. New cases of hypogonadism,
hypothyroidism, and hypoadrenalism occurred in 4 of 77 patients (5.2%), 3 of 95 patients (3.2%), and 6 of 100 patients at risk
(6.0%), respectively. Conclusion. In a highly selected group of acromegalic patients, GK treatment had good eﬃcacy and safety.
1.Introduction
Acromegaly is an endocrine disorder that results from chro-
nic secretion of abnormally high amounts of growth hor-
mone. It is associated with increased morbidity and mortal-
ity; mortality is 2-3 times that of an age- and sex-matched
normal population. Therapeutic options currently consist of
surgicalremovalofthepituitarytumor,somatostatinanalogs
(SSA), GH receptor antagonists, dopamine agonists, and
radiation therapy. The aims of therapy are to restore GH
and IGF-I levels to normal and control tumor growth. Trans-
sphenoidal surgery is the treatment of choice in the majority
of acromegalic patients [1–5]. However, even in experienced
hands, surgery leads to remission of acromegaly in about
60% of patients [6–8]. Those not cured by surgery or who
have late recurrence of disease need other treatments, such as
drugs [9, 10] or radiation [11, 12].
Single-session radiosurgery with the Leksell Gamma
Knife (GK) permits to deliver high-dose radiation to a tar-
geted volume. The surrounding normal structuresare spared
because of the steep fall-oﬀ of radiation at the margins of
the lesion. Landolt et al. [13] showed that the highly precise
and potent radiation delivered by GK caused a more rapid
fall of GH levels than fractionated radiotherapy. However,
there are few published data about the long-term results in
acromegalic patients of radiosurgical treatment, including
our previous study on a smaller group of patients with shor-
ter follow-up [14].
T h ea i mo fo u rs t u d yw a st oe v a l u a t et h ee ﬃcacy and
safety of GK in a homogeneous cohort of acromegalic pa-
tients who had previously undergone maximal surgical de-
bulking.
2.ClinicalMaterialandMethods
2.1. Patient Population. We included in the study 112 con-
secutive patients who were treated with GK for residual or
recurrent acromegaly, between January 1994 and December
2010. Diagnosis of active acromegaly was based on the clin-
ical picture, GH levels not suppressed less than 1ng/mL
after a glucose load, and an elevated age- and sex-adjusted
IGF-I level. Moreover, magnetic resonance imaging (MRI)
showed a residual or recurrent pituitary tumor in each
patient. The mean age at treatment was 42.2 ± 1.1y e a r s
(range 22–67 years). There were 68 women (60.7%) and 44
men (39.3%). Ninety-one patients (81.2%) had undergone2 International Journal of Endocrinology
Table 1: General characteristics of the population.
Characteristic
Sex
Male, n (%) 44 (39.3%)
Female, n (%) 68 (60.7%)
Age at GK (yr)
Mean (±SEM) 42.2 (±1.1)
Previous surgery
Once, n (%) 91 (81.2%)
Twice, n (%) 19 (17.0%)
>Twice, n (%) 2 (1.8%)
Hyperprolactinemia
n (%) 6 (5.4%)
Neuro-ophthalmological examination
Normal, n (%) 108 (96.4%)
Abnormal, n (%) 4 (3.6%)
Follow-up (months)
Median (range) 71 (6–184)
Tumor volume (cc)
Mean ± SEM (range) 1.8 ±0.2 (0.1–7.2)
Prescription dose (Gy)
Mean ± SEM (range) 22.5 ±0.3 (12–25)
surgery once, nineteen (17.0%) twice, and two patients
(1.8%) four times. Hyperprolactinemia was detected in six
patients (5.4%). Neuro-ophthalmological examination was
normal in hundred eight patients (96.4%) and abnormal in
four (3.6%) (Table 1).
From 1994 to 2000, concomitant therapy with SSA was
permitted according to patient’s preference. After the release
of one study that suggested a radioprotective eﬀect of SSA
[15],weadvised,whenfeasible,toquitsuchtreatmentbefore
GK. Because of this policy, only 20 patients (17.9%) were
receiving SSA at the time of GK. Medical treatment was not
initiated (66 patients) or was discontinued (36 patients) at
least 4 months or 2 weeks before GK, depending on the for-
mulation of the drug. Eleven patients (9.8%) continued tak-
ing dopamine agonists until the treatment with GK was per-
formed. Standard informed consent was obtained from each
patient undergoing GK. No patient was taking the GH-anta-
gonist Pegvisomant.
2.2. Clinical and Hormonal Evaluation. Evaluation of pitu-
itary function included measurement of free urinary cortisol
excretion and basal serum GH, IGF-I, free T3,f r e eT 4,T S H ,
L H ,F S H ,P R L ,c o r t i s o l ,t e s t o s t e r o n e( i nm e n ) ,a n d1 7 -
beta-estradiol levels (in premenopausal women). Neurooph-
thalmological examination included visual acuity testing,
oculomotor function, and automated perimetry. During
follow-up,GHandIGF-Ilevelsdeterminedwithoutanycon-
comitantmedicaltherapyorafteratleast4monthsofdiscon-
tinuation of SSA were considered as oﬀ treatment. Scheduled
follow-up studies included MRI and neuroophthalmological
examination 6, 12, 24, 36, and 48 months after GK and
then at 2-year intervals, whereas GH, IGF-I, and pituitary
function were determined at 6-month intervals for the ﬁrst 2
years and then yearly thereafter or when clinically indicated.
All examinations were performed at the Istituto Scien-
tiﬁco San Raﬀaele whenever possible. Otherwise, the refer-
ring physicians performed testing at a local facility, and the
results were sent to us for review. During the study period, a
variety of assays were used to determine IGF-I levels. When
indicated, we converted IGF-I levels into the multiple of the
upper normal limit (mUNL).
The criterion for remission of acromegaly after GK was
the achievement of normal age- and sex-adjusted IGF-I in
combination with a GH level less than 2.5ng/mL with-
out concomitant treatment with GH-suppressive drugs. Pa-
tients who still needed GH-suppressive drugs were not con-
sidered in remission, irrespective of IGF-I and GH levels.
Hypogonadotropic hypogonadism was diagnosed in preme-
nopausal women with amenorrhea and in men with subnor-
mal testosterone levels. Low or normal gonadotropin levels
were also required in both sexes. Hypogonadism was also
assigned to postmenopausal women with inappropriately
normal gonadotropin levels; three premenopausal women
taking estrogens were excluded from the analysis of gonadal
function. Secondary hypothyroidism was diagnosed in pa-
tients with low free T4 level and normal or suppressed TSH
concentration;fourpatients,alreadyonT4 replacementther-
apy because of other thyroid disorders, were excluded from
this analysis. Secondary hypoadrenalism was diagnosed by
low 24h free urinary cortisol and morning serum cortisol
(<50ng/mL) levels. Moreover, patients with serum cortisol
levels in the lower half of the normal range were also started
on a replacement therapy if they had symptoms of hypoad-
renalism.
2.3. Gamma Knife Radiosurgery. A Leksell stereotactic head
frame (model G; Elekta Instruments, Stockholm, Sweden)
waspositionedundermildsedationandafterapplicationofa
local anesthetic agent. Magnetic resonance images (Siemens,
Magneton Vision, 1,5 Tesla, Erlangen, Germany; Philips,
Aciva, 1,5 Tesla, Eindhoven, The Netherlands) were perfor-
med for tumor visualization. The MRI sequences were:
T1-weighted and T2-weighted without contrast and T1-wei-
ghted with contrast; slices were performed every 2mm on
three planes. Treatment was then planned with the KULA
dose-planning software until 1995 and the Leksell Gamma-
Plan system (Elekta Instruments) thereafter. GK was per-
formedusinga201-source60Cogammaknife(modelBuntil
December 2001 and model C thereafter). A neurosurgeon
delineated the target and one radiotherapist approved the
deﬁnitive radiosurgical planning. The entire residual tumor
was covered within the 50% isodose line. The mean tumor
volume was 1.8 ±0.2cc (range 0.1–7.2cc). The goal of treat-
ment was to deliver 25Gy to the margin of the tumor. The
mean prescription dose was 22.5 ± 0.3Gy (range 12–25Gy).
Multiple isocenters were distributed throughout the target
volume to conform the dose to the tumor margins. To this
aim, small collimator sizes (4 and 8mm) were used, and
frequent source blocking was applied to obtain a sharper
dose decrease toward the optic nerves, chiasm, and pituitary
stalk. The dose to the tumor was decreased, when necessary,International Journal of Endocrinology 3
to keep a maximal dose of 10Gy to the optical pathway. All
patients were discharged the day after GK treatment.
2.4.StatisticalAnalysis. Continuousvariableswereexamined
for homogeneity of variance by the Kolmogorov-Smirnov
test. For continuous variables with a normal distribution,
the mean (SEM) is reported. For variables not normally dis-
tributed, the median and interquartile ranges (IQRs) are re-
ported. The Wilkoxon signed-rank test for paired data was
used to compare GH and IGF-I levels before and after GKR.
Estimates of the cumulative event rate were calculated by
the Kaplan-Meier method, and diﬀerences in subgroups of
patients were tested by the log-rank test. Data for patients
who were lost to follow up or who did not reach remission
of disease were censored at the time of the last hormonal
evaluation. Adjusted analysis of the primary outcome, that
is, remission of acromegaly, was performed with the use of a
Cox proportional-hazards regression model with the factors
that had a P<0.10 in the univariate analysis plus preiden-
tiﬁed covariates of interest. A probability value of less than
0.05 was considered to indicate statistical signiﬁcance, and
all reported values are two sided. All calculations were
performed using a commercially available statistical software
package (SPSS 11.0 for Mac OS X; SPSS Inc., Chicago,
IL).
3. Results
3.1. Long-Term Eﬀects of GK on GH and IGF-I Levels. The
median follow-up was 75 months (IQR 38–111 months;
range 6–192 months). Seventy-nine patients (70.5%) did not
receive any medical treatment at their last follow-up visit.
Their median serum GH level fell from a baseline value of
5.1ng/mL (IQR 2.9–10.0) to a one of 1.0ng/mL (IQR 0.6–
2.1; P<0.001). Similarly, the median IGF-I level fell from
500ng/mL (IQR 400–728) to 208ng/mL (IQR 155–288; P<
0.001) (Table 2).
Remission of disease occurred in 68 patients (60.7%).
Survival analysis showed that the probability to achieve
remission of acromegaly was 30.7% at 3 years (95% conf-
idence interval (CI) 21.5–39.9%) and 56.9% at 5 years (95%
CI 46.5–67.3%). Further cases of remission occurred during
prolonged follow-up so that the estimated 10-year rate of
remission was 80.4% (95% CI 68.2–92.6%). Only two pa-
tients had recurrences of acromegaly 1 and 10 years after re-
mission. The ﬁrst patient was successfully treated with SSA,
while the second patient, who was resistant to somatostatin
analogues, received a second course of GK treatment. No
other recurrence occurred in the other 61 patients. Other 18
patients (16.1%) had remission of disease while continuing
SSA. Three patients normalized IGF-I levels after starting
therapy with a GH receptor antagonist 3–6yr after GK. In
our study we did not ﬁnd out any correlation between treat-
ment volume and failure or remission rate.
3.2. Tumor Growth Control. At the last follow-up, tumor size
remained unchanged in 61 patients (54.5%), decreased in 48
patients (42.9%), and increased in the remaining 3 patients
(2.7%) (Table 3).
Table 2: Long-term eﬀects of GK on GH and IGF- I levels in
patients without medical treatment (N = 79).
Basal GH level (ng/mL) Median (IQR)
Before GK 5.1 (2.9–10.0)
After GK 1.0 (0.6–2.1)
Basal IGF-I level (ng/mL) Median (IQR)
Before GK 500 (400–728)
After GK 208 (155–288)
Table 3: Tumor growth control after GK treatment.




Growth of the tumor occurred 4, 5, and 10 years after
GK, respectively. However, one of the patients did not show
recurrence of GH hypersecretion. In all three cases, recur-
renceoccurredinanareathatwasnotcov eredbyGKbecause
MRI at the time of treatment did not show any pathological
tissue in that location. Two patients were treated with SSA
and the third by a second GK. In all cases, there was no fur-
ther tumor growth.
3.3. Side Eﬀects of GK. No serious side eﬀects occurred after
GK. Ten patients (9.7%), three of whom already sympto-
maticbeforeGK,complainedofsevereheadacheforatleast1
month after GK. No patient had deterioration of visual func-
tion or oculomotor function. One patient had CSF rhino-
liquorrhea necessitating surgical repair 18 months after GK.
The patient underwent transsphenoidal surgery with autol-
ogous fat apposition to seal the leak. Eight of 102 patients
(7.8%) experienced a new deﬁcit of pituitary function (the
remaining patient had hypopituitarism before GK). In more
detail, new cases of hypogonadism occurred in four of the
82 patients at risk (4.9%). New cases of hypothyroidism
occurred in four of the 103 patients at risk (3.9%), and new
cases of hypoadrenalism occurred in six (5.5%) of the 109
patientsatrisk.Inallcases,replacementtherapywasinitiated
accordingly. No cases of diabetes insipidus occurred after
GK.
4. Discussion
Radiotherapy has the potential to obtain deﬁnitive remission
of acromegaly, but the disadvantages of radiation include
slow-onset eﬀect on GH secretion, high risk of hypopitu-
itarism, and rare but severe side eﬀects, such as radionecrosis
and secondary brain tumors [16, 17]. However, most infor-
mation on the positive and negative eﬀects of radiotherapy
pertains to fractionated radiotherapy [11, 12, 18, 19]. GK has
the advantage of delivering a highly focused radiation in a
singlefractiontothetargetlesion.Thisshouldleadtoafaster
decline of GH and IGF-I levels and a lower risk of complica-
tions. If such promises can be demonstrated in a suﬃcient4 International Journal of Endocrinology
number of patients, the indications for GK might be broade-
ned in the future [1].
Our data, in a selected population of patients, show that
remission occurred throughout the follow-up period, appro-
aching almost 85% 10yr after GK. Moreover, 18 patients,
who had complete or partial resistance to SSA, achieved re-
mission of disease while continuing the drug after GK.
Recurrence of disease once remission had been achieved was
quite uncommon.
Previous studies reported mixed results [20–25]. Using
biochemical criteria similar to ours, remission of acromegaly
occurred at 5yr in 56–60% of cases [23, 24], whereas lower
rates(29–30%)havebeenreportedbyotherauthors[20,21].
Minor diﬀerences in the criteria of remission are unlikely
to explain these diﬀerences because normalization of age-
and sex-adjusted IGF-I levels was common to all these series.
We, as other authors, did not require suppression of GH
levels after oral glucose tolerance test as a criterion of remis-
sion because radiation therapy may alter GH feedback regu-
lation,thusmakingtheinterpretationofGHdynamictesting
more diﬃcult [26]. Indeed, Powell and coworkers [27]
showed a clear overlap in the postglucose GH levels in 15
irradiatedpatients,whosediseasestatuswasdeﬁnedbyIGF-I
levels. GH and IGF-I levels before GK treatment and in
the absence of concomitant GH-suppressive therapy were
inversely associated with remission. The other variables, in-
cluding sex, age, year of GK, concomitant treatment with
SSA, and radiation dose to the tumor margin, were not in-
dependently associated with outcome. In a univariate analy-
sis, basal GH and IGF-I levels oﬀ medication were inversely
relatedtoasuccessfuloutcomeintwoseries[21,23],whereas
Pollock et al. [24], who also used a multivariate analysis,
found that only baseline IGF-I levels had an independent
predictive value. Interestingly, the same relationship between
baseline hormone levels and remission of acromegaly also
exists after conventional radiotherapy [12, 28–30]. Despite
some exceptions to this supposition [18, 20, 25, 31], it seems
reasonable that the less hormonally active tumors will nor-
malize earlier because the kinetic of GH reduction after radi-
ation seems to be independent of the starting GH level [21].
Therefore, maximal surgical debulking before GK should en-
hance the subsequent probability of success. In keeping with
another series, [24] we found that the prescription dose to
the tumor was not independently associated with remission
of disease. The role of concomitant therapy with SSA has
been debated after the report of Landolt et al. [15], which
showed a clearly reduced eﬃcacy of GK in patients while on
medication. The supposed radioprotective eﬀect of SSA has
been conﬁrmed by some [24] but not all authors [20, 21].
Only a randomized prospective study would give the ﬁnal
answertothisquestion.Inthemeantimeandinkeepingwith
other authors’ point of view [21, 32, 33], we prefer quitting
SSA before GK treatment, when clinically feasible.
Reduction of tumor size after GK occurred in 48.5% of
our patients, but it was not related to biochemical outcome,
as already reported by Jeˇ zkov´ a et al. [23]. Three patients
showed growth of residual tumor located outside the area
initially covered by GK. We described two similar cases in
patients with a nonfunctioning pituitary adenoma [34].
Continuous MRI follow-up is therefore necessary, especially
in patients without remission of disease. Determining the
safety of GK is of paramount importance to broaden its use
inacromegaly.Theconventionalradiosurgicaltolerancedose
of the anterior visual pathways is considered to be 8 to 10Gy,
and it is assumed that there is no serious risk of visual def-
icit due to radiation if no more than 15Gy are delivered [13,
35–37]. In our study we did not experience any visual distur-
bances or deﬁcits after Gamma Knife maintaining the dose
to the optic pathway up to 10Gy.
N os e r i o u ss i d ee ﬀect attributable to GK has occurred
in our series. A similar safety proﬁle has been described by
other authors [20, 23]. Only two series [21, 24]r e p o r t e d
serious side eﬀects in three patients. However, they all had
received conventional radiotherapy before GK, suggesting
that the cumulative exposure to radiation rather than GK
itself was the principal risk factor for serious complica-
tions.
New deﬁcit of pituitary function occurred rarely in our
series.Inonestudywithameanfollow-upof54months[23],
new cases of hypogonadism, hypothyroidism, and hypoad-
renalism occurred in 41.1, 31.7, and 14% of the patients at
risk, respectively. The rather high rate of hypopituitarism in
that study might be attributed to the high percentage of
patients (12.5%) who had previously received conventional
radiotherapy and to the higher median radiation dose to the
tumor margin (35 versus 22.5Gy). The latter factor is pro-
bably the most important because another series that used
a median margin dose similar to ours (20Gy) had 5.3, 0,
and 7.7% new cases of hypogonadism, hypothyroidism, and
hypoadrenalism, respectively [20]. Pollock et al. [24]r e p o r -
t e dt h a t1 3o f3 9p a t i e n t s( 3 3 % )s u ﬀered a new pituitary
deﬁcit after a median follow-up of 63 months.
A direct comparison between the results of GK and frac-
tionated radiotherapy is diﬃcult to perform because patients
selected to undergo GK may have more favorable charac-
teristics, that is, smaller tumor size and lower GH levels,
than those receiving fractionated radiotherapy. A faster nor-
malization of IGF-I levels has been found in patients treated
by GK than in a group of historical controls treated at the
same institution by fractionated radiotherapy [13]. The risk
of new-onset hypopituitarism seems, on average, to be lower
for GK than fractionated radiotherapy. Only prospective,
randomized, controlled studies would clarify the issue but
are unlikely to be performed.
5. Conclusion
In conclusion, our study wants to demonstrate that, in a
highly selected group of acromegalic patients subjected to
previous surgery at our center, GK was eﬀective and safe.
This may lead to reconsider the role of GK in the therapeutic
algorithm of acromegaly. GK treatment might be considered
as an alternative to lifelong treatment with SSA or GH recep-
tor antagonists, particularly in patients with small tumor
residue located away from the optic pathway and the residual








MRI: Magnetic resonance imaging
mUNL: Multiple of the upper normal limit
SSA: Somatostatin analog.
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